{
    "id": 12304,
    "fullName": "ERBB3 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) dec exp indicates decreased expression of the Erbb3 (Her3) protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "dec exp",
    "createDate": "09/22/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3179,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB3 (HER3) knock-down increased sensitivity of colorectal cancer cell lines harboring ERBB2 (HER2) amplification to growth inhibition by Tykerb (lapatinib) in culture (PMID: 26296355).",
            "molecularProfile": {
                "id": 12427,
                "profileName": "ERBB2 amp ERBB3 dec exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3180,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB3 (HER3) knock-down increased sensitivity of gastric cancer cell lines harboring ERBB2 (HER2) amplification to growth inhibition by Tykerb (lapatinib) in culture (PMID: 26296355).",
            "molecularProfile": {
                "id": 12427,
                "profileName": "ERBB2 amp ERBB3 dec exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3655,
                    "pubMedId": 26296355,
                    "title": "Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26296355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5546,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung carcinoma cell lines demonstrating lower basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) were resistant to Pan-HER in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20977,
                "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5547,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines demonstrating lower basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) were resistant to Pan-HER in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20977,
                "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 12426,
            "profileName": "ERBB3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 12427,
            "profileName": "ERBB2 amp ERBB3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20977,
            "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}